Literature DB >> 31738564

Detection of Ovarian Cancer Using Samples Sourced from the Vaginal Microenvironment.

Melissa M Galey1, Alexandria N Young1, Valentina Z Petukhova1, Mingxun Wang2, Jian Wang2, Amrita Salvi1, Angela Russo1, Joanna E Burdette1, Laura M Sanchez1.   

Abstract

Mass spectrometry (MS) offers high levels of specificity and sensitivity in clinical applications, and we have previously been able to demonstrate that matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS is capable of distinguishing two-component cell mixtures at low limits of detection. Ovarian cancer is notoriously difficult to detect due to the lack of diagnostic techniques available to the medical community. By sampling a local microenvironment, such as the vaginal canal and cervix, a MS based method is presented for monitoring disease progression from proximal samples to the diseased tissue. A murine xenograft model of high grade serous ovarian carcinoma (HGSOC) was used for this study, and vaginal lavages were obtained from mice on a weekly basis throughout disease progression and subjected to our MALDI-TOF MS workflow followed by statistical analyses. Proteins in the 4-20 kDa region of the mass spectrum yielded a fingerprint that we could consistently measure over time that correlated with disease progression. These fingerprints were found to be largely stable across all mice, with the protein fingerprint converging toward the end point of the study. MALDI-TOF MS serves as a unique analytical technique for measuring a sampled vaginal microenvironment in a specific and sensitive manner for the detection of HGSOC in a murine model.

Entities:  

Keywords:  MALDI-TOF MS; detection; disease progression; fingerprints; lavage; microenvironment; murine model; ovarian cancer; proteins; vaginal

Mesh:

Substances:

Year:  2019        PMID: 31738564      PMCID: PMC7020100          DOI: 10.1021/acs.jproteome.9b00694

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  30 in total

Review 1.  Characterization of intact microorganisms by MALDI mass spectrometry.

Authors:  C Fenselau; P A Demirev
Journal:  Mass Spectrom Rev       Date:  2001 Jul-Aug       Impact factor: 10.946

2.  The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.

Authors:  J R van Nagell; P D DePriest; M B Reedy; H H Gallion; F R Ueland; E J Pavlik; R J Kryscio
Journal:  Gynecol Oncol       Date:  2000-06       Impact factor: 5.482

3.  Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

Authors:  Kenneth P Olive; David A Tuveson; Zachary C Ruhe; Bob Yin; Nicholas A Willis; Roderick T Bronson; Denise Crowley; Tyler Jacks
Journal:  Cell       Date:  2004-12-17       Impact factor: 41.582

4.  Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.

Authors:  Jamie N Bakkum-Gamez; Nicolas Wentzensen; Matthew J Maurer; Kieran M Hawthorne; Jesse S Voss; Trynda N Kroneman; Abimbola O Famuyide; Amy C Clayton; Kevin C Halling; Sarah E Kerr; William A Cliby; Sean C Dowdy; Benjamin R Kipp; Andrea Mariani; Ann L Oberg; Karl C Podratz; Viji Shridhar; Mark E Sherman
Journal:  Gynecol Oncol       Date:  2015-02-10       Impact factor: 5.482

5.  Proteomic analysis of human cervico-vaginal fluid.

Authors:  Julie L V Shaw; Christopher R Smith; Eleftherios P Diamandis
Journal:  J Proteome Res       Date:  2007-06-14       Impact factor: 4.466

6.  DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.

Authors:  David Klinkebiel; Wa Zhang; Stacey N Akers; Kunle Odunsi; Adam R Karpf
Journal:  Mol Cancer Res       Date:  2016-06-03       Impact factor: 5.852

Review 7.  MALDI-TOF MS as evolving cancer diagnostic tool: a review.

Authors:  Miguel Angel Merlos Rodrigo; Ondrej Zitka; Sona Krizkova; Amitava Moulick; Vojtech Adam; Rene Kizek
Journal:  J Pharm Biomed Anal       Date:  2014-03-15       Impact factor: 3.935

8.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Authors:  Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  JAMA       Date:  2011-06-08       Impact factor: 157.335

9.  Evaluating cell lines as tumour models by comparison of genomic profiles.

Authors:  Silvia Domcke; Rileen Sinha; Douglas A Levine; Chris Sander; Nikolaus Schultz
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  A feasibility study to identify proteins in the residual Pap test fluid of women with normal cytology by mass spectrometry-based proteomics.

Authors:  Kristin Lm Boylan; Somaieh Afiuni-Zadeh; Melissa A Geller; Kayla Hickey; Timothy J Griffin; Stefan E Pambuccian; Amy Pn Skubitz
Journal:  Clin Proteomics       Date:  2014-07-14       Impact factor: 3.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.